Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

ABSTRACT: The role of immunosuppression in IgA nephropathy (IgAN) is controversial. In the Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) Trial, 162 patients with IgAN and proteinuria >0.75 g/d after 6 months of optimized supportive care were randomized into two groups: continued supportive care or additional immunosuppression (GFR≥60 ml/min per 1.73 m²: 6-month corticosteroid monotherapy; GFR=30-59 ml/min per 1.73 m²: cyclophosphamide for 3 months followed by azathioprine plus oral prednisolone). Coprimary end points were full clinical remission and GFR loss ≥15 ml/min per 1.73 m² during the 3-year trial phase. In this secondary intention to treat analysis, we separately analyzed data from each immunosuppress

SUBMITTER: Rauen T 

PROVIDER: S-EPMC5748925 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature